Skip to main content

Benign prostatic hyperplasia

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Enlarged prostate article more useful, or one of our other health articles.

Benign prostatic enlargement

The term benign prostatic hypertrophy is also used but technically it is incorrect. Hypertrophy means enlargement of the components without an increase in their numbers as happens with muscle fibres. Hyperplasia is an increase in the number of the components and this is typical of glandular enlargement.

Continue reading below


Benign prostatic hyperplasia (BPH) is an increase in size of the prostate gland without malignancy present and it is so common as to be normal with advancing age. It seems likely that the nature of BPH is a failure of apoptosis (natural programmed death of cells) and that some of the drugs used to treat it may induce that process1 .

The prostate secretes about 20-30% of the volume of seminal fluid. It is a hormone-dependent gland and BPH does not occur in castrated men.

It should be borne in mind that lower urinary tract symptoms (LUTS) and BPH are not synonymous. Prevailing European guidelines suggest that because BPH is so common in older men, it should not be looked on as the only possible pathology in patients presenting with LUTS. The doctor assessing a patient with LUTS should take an holistic view bearing in mind the full range of causes and the possibility of co-existing morbidities2 .


BPH affects the quality of life of about 40% of men in their fifth decade and 90% of men in their ninth decade2 . It is unusual before the age of 45 and affects men of Afro-American origin more severely than white men, possibly due to higher testosterone levels, 5-alpha-reductase activity, androgen receptor expression and growth factor activity.

One study found some correlation between LUTS and increased prostate volume3 . Another study found that the mean length of prostate increased faster than the height and width, especially after the age of 60 years. The transitional zone volume and transitional zone length had a higher correlation with the International Prostate Symptom Score (I-PSS) than total prostate volume4 .

The prostate increases in size with passing years but at a decelerating rate. Between the ages of 31 and 50 it doubles in size every 4.5 years but this rate reduces subsequently5 .

Continue reading below


History should focus on a number of specific features that are typical of the disease6 . This should be followed by the I-PSS to give an assessment of the effect on the quality of life. If surgery seems likely (and bearing in mind the age of most men who present with this condition) further questions to assess fitness for surgery may be in order.

  • Urinary frequency is often a presenting symptom. Ask how many times a day he needs to void and how often he has to rise at night. Ask also if he passes small or large volumes of urine each time. When enquiring about urinary frequency, it is necessary to distinguish frequent passage of small volumes from polyuria. To this end it may be helpful to complete a frequency/volume chart.

  • Urinary urgency may occur and manifests as a need to pass urine quickly for fear of incontinence.

  • Hesitancy occurs when he has to stand at the toilet for a while before he can initiate micturition. There is usually a poor stream and dribbling of urine too and he may stop during the act.

  • Incomplete bladder emptying gives the sensation of still having urine in the bladder, no matter how often he goes. He may even be able to pass more immediately after he has finished.

  • There may be a need to push or strain, increasing the risk of micturition syncope.

The I-PSS is a quantitative and validated technique based on eight questions and a further quality-of-life question. The results are summated to give a figure for the degree of trouble caused by the condition.

The I-PSS is free for the use of individual clinicians and non-funded research7 . The results are scored and severity of the symptoms is classified according to the score:

Interpretation of I-PSS score






Mild symptoms

Moderate symptoms

Severe symptoms


  • Examination of the abdomen includes checking for a palpable bladder. This may indicate chronic outflow obstruction or a neurogenic bladder. To exclude the latter, an enquiry about motor or sensory loss along with checking knee and ankle jerks and plantar responses should suffice. Any further abnormalities require a full neurological history and examination.

  • Digital rectal examination (DRE) includes noting the tone of the anal sphincter and the pelvic floor. It may be poor with a neurogenic bladder. The size of the prostate is assessed. Urologists report their findings in terms of the size of the prostate, a normal gland in a young adult weighing about 20 g. A useful guide for those less familiar with prostates is that a finger's breadth represents about 15 to 20 g and so a gland that is three fingers in breadth across is 45 to 60 g. Symptoms are unusual below two fingers in breadth. It is also important to note the texture and contour of the gland. It should be firm but not hard, and smooth without nodules. The median sulcus should be clearly defined. A gland that is hard rather than firm, nodular and lacks a clear median sulcus suggests carcinoma of prostate.

  • If an elderly person is likely to need surgery, a brief check of the cardiovascular and respiratory systems is also needed.

Continue reading below



Check urine by dipstick and send MSU for microscopy and culture.


  • Routine blood tests include:

    • U&E and creatinine

    • FBC

    • LFTs

    Abnormal LFTs may indicate other disease. Isolated elevation of alkaline phosphatase can occur:

    • If the prostate is malignant and has metastasised to bone.

    • In an elderly person, where it may represent undiagnosed Paget's disease of bone.

  • PSA is elevated with a large, benign prostate. Experts consider that gentle DRE is unlikely to raise the PSA result. A combination of clinical examination and PSA levels may be a better way of attempting to differentiate between a benign and malignant prostate gland, although evidence to support this may be lacking8 . It should be recognised that normal PSA values change with age9 :

PSA Cut-off Values

Age (years)

PSA Cut-off


2.5 micrograms/litre or higher


3.5 micrograms/litre or higher


4.5 micrograms/litre or higher


6.5 micrograms/litre or higher

There are no age-specific reference limits for men older than 80 years of age. Whether you are referred will depend on your discussion with your doctor.

Patients (and sometimes doctors) expect a test to give a simple affirmative or negative answer and so a booklet to help understand the PSA test may be of value. A high result may occur in benign disease and may be associated with an increased risk of having LUTS requiring treatment10 .


Imaging may also be necessary if there is any suggestion of urinary tract obstruction11 .

Ultrasound examination of the prostate may be used prior to surgery or if it will assist choice of medical therapy.

Other investigations

  • The European Association of Urology suggests that post-void residual bladder volume should be part of any routine assessment of male LUTS2 . It can be estimated by passing a catheter and measuring the volume but ultrasound is comfortable, non-invasive and accurate. This is only currently recommended as part of specialist assessment by the National Institute for Health and Care Excellence (NICE)12 .

  • Further investigations that may possibly be required include assessment of urine flow rate. It should be used as a baseline before embarking on any treatment, whether medical or surgical. The maximal flow rate (Qmax) is the single best measurement but a low Qmax does not help to differentiate between obstruction and poor bladder contractility. More detailed analysis requires a pressure flow study. A Qmax value over 15 mL/second is usually considered normal. A Qmax below 7 mL/second is accepted as low. Results can vary according to effort and volume and so the usual compromise is to obtain at least two readings with at least 150 mL of urine each time.

  • Pressure studies are rather invasive but may be necessary if there is suspected bladder neck obstruction. A voiding pressure above 60 cm water with a Qmax of under 15 mL/second is regarded as diagnostic.

  • Endoscopy may be required. A flexible cystoscope can be used as an outpatient procedure with a topical anaesthetic gel. It takes several minutes and may be useful if urethral stricture is suspected. This may follow prolonged indwelling catheter or gonococcal urethritis. It may also be used if a lesion in the bladder is suspected.

Diagnostic algorithm including only objective variables (age, I-PSS and PSA), allows GPs to diagnose BPH accurately in approximately three quarters of patients spontaneously reporting LUTS13 .

Indications for referral

In September 2020 and more recently in January 2021, NICE provided updated guidance on suspected cancer recognition and referral. There are no specific changes in these versions that relate to prostate cancer14 .

NICE recommends referral for the following:

Differential diagnosis

Management2 14 15

See also the separate Lower Urinary Tract Symptoms in Men article.

  • If symptoms are minimal, 'watchful waiting' (WW) is the most judicious option, provided that malignancy has been excluded16 . One study found that WW was more readily used by specialist than by primary care physicians17 . The three key components which seem to contribute to the effectiveness of this approach are reassurance, education and monitoring.

  • Other management does not always have to be surgical and there are several drugs which have proved useful to control the condition and they have been reviewed.

  • A trial of medical therapy may still be followed by surgery, if required.

  • Irrespective of the mode of management chosen after discussion with the patient, there should be periodic follow-up to assess progress, as the natural history is a tendency for symptoms to worsen.

  • Complications, as discussed at the end, may necessitate referral, even as an emergency.

  • There is some evidence supporting the use of lifestyle advice along with other modalities of treatment. BPH has been related to factors such as obesity and thus it is probably good to counsel patients on healthy diet regimens and involvement in exercise programmes if possible18 .


  • Alpha-adrenergic antagonists, or alpha-blockers, reduce the tone in the muscle of the neck of the bladder. They should be offered to men with moderate-to-severe voiding symptoms (corresponding to an I-PSS of 8 or more). There are alpha-1 receptors that are subdivided into types 1a, 1b and 1c. The alpha-1a is predominant in the prostate gland, bladder neck and urethra and the most selective drug available is tamsulosin16 . Prescribers of tamsulosin should be aware of the existence of intra-operative floppy iris syndrome, a condition which causes the iris to 'billlow out' during cataract surgery. This does not usually affect the long-term outcome but it can cause pain and prolong the recovery period. If warned, urologists can use techniques to minimise the risk of this occurring, so if GPs have prescribed tamsulosin, it is important for them to mention it in their referral letters19 .

  • Less selective alpha-blockers include doxazosin, terazosin, prazosin, alfuzosin and indoramin. The less specific effects may sometimes be beneficial. For example, if the patient has BPH and hypertension, one drug may be beneficial for both.

  • 5-alpha reductase inhibitor (5-ARI) drugs block the synthesis of dihydrotestosterone from testosterone and can reduce symptoms - eg, finasteride and dutasteride. They do work but it may take several months before benefit is noted. Unlike alpha-blockers, they have been shown to reduce the long-term risk (>1 year) of acute retention or need for surgery. They should be offered to men with LUTS and a prostate gland estimated to be larger than 30 g or PSA greater than 1.4 ng/mL and a high risk of progression15 .

  • For patients with bothersome moderate-to-severe LUTS not responding to monotherapy and with a prostate estimated to be larger than 30 g or PSA greater than 1.4 ng/mL, consider an alpha-blocker plus a 5-ARI. Treatment should be continued for at least one year.

  • There are a number of dietary supplements that are used in BPH. They are not available on FP10 but may be bought by the patient. Establishing an evidence base for the effectiveness of these products has been difficult due to variations in methodological techniques. One review of the literature reported some evidence for the effectiveness of beta-sitosterol, Pygeum africanum and Cernilton® but not for several other compounds20 .

Certain caveats should be observed:

  • Avoid alpha-blockers in those with postural hypotension or micturition syncope.

  • 5-ARIs may have an adverse effect on sexual performance and direct questioning about sexual history is needed. Problems include decreased libido, ejaculation disorder and erectile dysfunction, which may continue after the medication has been stopped. Generally, adverse effects are less than with alpha-blockers.

  • Studies suggest that alpha-blockers continue to exert efficacy for at least four years.

  • Due to their slow onset of action, 5-ARIs should be continued for many years.


Surgery is usually reserved for those with a large prostate gland or failure to respond to an adequate trial of medical therapy2 12 .

  • Surgery is required if there is acute urinary retention, failed voiding trials, recurrent gross haematuria, UTI, renal insufficiency due to obstruction or failure of medical treatment.

  • Open prostatectomy - transurethral vaporisation of the prostate (TUVP) is reserved for those with a prostate larger than 80 g, bladder stones or bladder diverticula and patients who cannot be positioned for transurethral surgery. The inner core of the prostate adenoma is shelled out, leaving the peripheral zone behind. There may be significant blood loss requiring transfusion. Open prostatectomy usually has excellent results in terms of improvement of urinary flow and urinary symptoms.

  • Transurethral resection of the prostate (TURP) is now the standard technique. A working sheath is placed in the urethra through which a hand-held device with an attached wire loop is placed. A cutting diathermy is run through the loop so that it can be used to shave away prostatic tissue. When successful, it is an excellent operation that does not involve entering the abdomen but it can have complications. Bleeding may be difficult to control. Irrigating fluid may be absorbed into the circulation via cut veins. An indwelling catheter is required until bleeding has stopped. Urethral stricture can occur. There can be retrograde ejaculation after operation or damage to the nerves can cause erectile dysfunction.

  • The UroLift System is a minimally invasive procedure, which should be considered as an alternative to TURP and holmium laser enucleation of the prostate (HoLEP). It can be done as a day-case or outpatient procedure for people aged 50 and older with a prostate volume between 30 and 80 ml. Evidence supports the case for adopting the UroLift System for treating lower urinary tract symptoms of BPH21 . The UroLift System relieves lower urinary tract symptoms, avoids risk to sexual function, and improves quality of life.

  • HoLEP is equally effective, but in comparison over five years, if done as a day‑case procedure, UroLift is estimated to save, £1,230 per person.

  • Rezum®22 has been approved by NICE as an option for for treating lower urinary tract symptoms secondary to BPH. Rezum® technology uses water vapour to destroy excess prostate tissue, with the aim of relieving symptoms. The procedure can be carried out as a day case and is cost-saving compared to TURP. The incidence of sexual dysfunction after treatment with Rezum® was low, with a few people reporting a decrease in ejaculatory function but little change in erectile function.

  • Estimated prostate size smaller than 30 g: transurethral incision of the prostate (TUIP) or transurethral needle ablation (TUNA) can be offered as an alternative to TURP for patients wishing to avoid, or who are unfit for, more invasive surgery. Both treatments, however, have a higher recurrence rate than TURP. If the prostate size is larger than 80 g, this narrows the options to TURP, TUVP or HoLEP.

  • It should be noted that surgical options are unlikely to be definitive procedures.

  • Newer techniques such as prostate artery embolisation are being researched to assess safety and efficacy23 .


Bladder outlet obstruction can result in:

BPH is not considered to be a precursor of prostate cancer. It is likely that although BPH may not make prostate cancer more likely to occur, it may increase the chance of diagnosing an incidental cancer24 .

Some authorities recommend annual screening for prostate cancer with a digital rectal examination and a serum PSA (after discussing the potential risks and benefits of PSA testing) for patients between 40 and 75 years of age. However this recommendation is not universal and is not included in any national guideline.

Further reading and references

  • Foo KT; What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol. 2019 Jul;37(7):1293-1296. doi: 10.1007/s00345-019-02691-0. Epub 2019 Feb 25.
  • Te AE; Recent advances in prostatectomy for benign prostatic hyperplasia. F1000Res. 2019 Aug 29;8. doi: 10.12688/f1000research.18179.1. eCollection 2019.
  • Albisinni S, Aoun F, Roumeguere T, et al; New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urol Nefrol. 2017 Apr;69(2):119-132. doi: 10.23736/S0393-2249.16.02743-0. Epub 2016 Sep 28.
  1. Desiniotis A, Kyprianou N; Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opin Ther Targets. 2011 Dec;15(12):1405-18. Epub 2011 Dec 13.
  2. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO); European Association of Urology (2015)
  3. Wang JY, Liu M, Zhang YG, et al; Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey. Chin Med J (Engl). 2008 Oct 20;121(20):2042-5.
  4. Zhang SJ, Qian HN, Zhao Y, et al; Relationship between age and prostate size. Asian J Androl. 2013 Jan;15(1):116-20. doi: 10.1038/aja.2012.127. Epub 2012 Dec 10.
  5. Simoneau AR, Gerner EW, Nagle R, et al; The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9.
  6. LUTS in men; NICE CKS, March 2019 (UK access only)
  7. International Prostate Symptom Score; Urological Sciences Research Foundation
  8. Djulbegovic M, Beyth RJ, Neuberger MM, et al; Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010 Sep 14;341:c4543. doi: 10.1136/bmj.c4543.
  9. PSA measurements, frequently-asked questions; British Association of Urological Surgeons, March 2016
  10. Rhodes T, Jacobson DJ, McGree ME, et al; Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men. J Urol. 2012 Jan;187(1):87-91. Epub 2011 Nov 16.
  11. Wilt TJ, N'Dow J; Benign prostatic hyperplasia. Part 1--diagnosis. BMJ. 2008 Jan 19;336(7636):146-9.
  12. Lower urinary tract symptoms in men: assessment and management; NICE Guidelines (June 2015)
  13. Carballido J, Fourcade R, Pagliarulo A, et al; Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial. Int J Clin Pract. 2011 Sep;65(9):989-96. doi: 10.1111/j.1742-1241.2011.02735.x. Epub 2011 Jul 7.
  14. Suspected cancer: recognition and referral; NICE guideline (2015 - last updated October 2023)
  15. Gontero P et al; Problem Based Urology, 2013.
  16. Wilt TJ, N'Dow J; Benign prostatic hyperplasia. Part 2 - management. BMJ. 2008 Jan 26;336(7637):206-10.
  17. Wei JT, Miner MM, Steers WD, et al; Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol. 2011 Sep;186(3):971-6. Epub 2011 Jul 24.
  18. Wang S, Mao Q, Lin Y, et al; Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):265-72. doi: 10.1038/pcan.2011.65. Epub 2011 Dec 20.
  19. Brogden PR, Backhouse OC, Saldana M; Intraoperative floppy iris syndrome associated with tamsulosin. Can Fam Physician. 2007 Jul;53(7):1148.
  20. Kim TH, Lim HJ, Kim MS, et al; Dietary supplements for benign prostatic hyperplasia: An overview of systematic reviews. Maturitas. 2012 Aug 7.
  21. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia; NICE Medical technologies guidance, May 2021
  22. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia; NICE Medical technologies guidance [MTG49], June 2020
  23. Prostate artery embolisation for benign prostatic hyperplasia; NICE Interventional Procedure Guidance, April 2013
  24. Chang RT, Kirby R, Challacombe BJ; Is there a link between BPH and prostate cancer? Practitioner. 2012 Apr;256(1750):13-6, 2.

Article history

The information on this page is written and peer reviewed by qualified clinicians.

symptom checker

Feeling unwell?

Assess your symptoms online for free